linkedin

Press Releases

Press Releases

Samsung Biologics showcases its newest CDO process platform, S-Cellerate™, at BPI 2021, offering expedited timeline to IND and BLA

BPI2_v2.png
BPI4.jpg
 

 

 

Samsung Biologics, a global contract development and manufacturing organization (CDMO), introduced its proprietary technology platform, S-Cellerate™, at the BioProcess International Conference (BPI 2021) to offer clients an integrated and seamless drug development solution resulting in accelerated timelines.

 

BPI 2021 took place both online and offline in Boston this year, allowing industry peers to engage and network and also have access to the latest technology trends. Samsung Biologics attended the event on-site to closely connect with industry experts and showcase S-Cellerate™ at a poster session while also hosting virtual meetings to provide clients with its end-to-end CDMO service offerings.

 

S-Cellerate™ is a drug development service platform which offers an expedited process for the development and commercialization of monoclonal antibodies. This platform includes two distinguished services: an accelerated CDO timeline to Investigational New Drug Application (IND), and a complete solution for commercialization to reach Biologics License Applications (BLA). With S-Cellerate™, clients are able to reach IND filings in as fast as 9 months, as well as access a full spectrum of services from process characterization and validation to BLA submission while maintaining the highest product quality and operational robustness.

 

“We are very pleased to showcase our innovative CDO service platform, S-Cellerate™, at BPI 2021,” said John Rim, CEO of Samsung Biologics. “By leveraging this proprietary drug development platform, our teams of experts will jointly provide seamless one-stop services to our clients, offering enhanced solutions that can help reduce both cost and time, catering to their specific needs.”

 

Samsung Biologics’ CDO business brings quality-driven development services at a greater speed. The company also operates a global R&D center in San Francisco, California, and with the launch of S-Cellerate™, along with its proprietary cell line development platform S-CHOice™, Samsung Biologics continues to provide competitive and innovative service offerings to clients, accelerating the speed of molecules to market.


 

BPI2_v2.png
BPI4.jpg
 

 

 

Samsung Biologics, a global contract development and manufacturing organization (CDMO), introduced its proprietary technology platform, S-Cellerate™, at the BioProcess International Conference (BPI 2021) to offer clients an integrated and seamless drug development solution resulting in accelerated timelines.

 

BPI 2021 took place both online and offline in Boston this year, allowing industry peers to engage and network and also have access to the latest technology trends. Samsung Biologics attended the event on-site to closely connect with industry experts and showcase S-Cellerate™ at a poster session while also hosting virtual meetings to provide clients with its end-to-end CDMO service offerings.

 

S-Cellerate™ is a drug development service platform which offers an expedited process for the development and commercialization of monoclonal antibodies. This platform includes two distinguished services: an accelerated CDO timeline to Investigational New Drug Application (IND), and a complete solution for commercialization to reach Biologics License Applications (BLA). With S-Cellerate™, clients are able to reach IND filings in as fast as 9 months, as well as access a full spectrum of services from process characterization and validation to BLA submission while maintaining the highest product quality and operational robustness.

 

“We are very pleased to showcase our innovative CDO service platform, S-Cellerate™, at BPI 2021,” said John Rim, CEO of Samsung Biologics. “By leveraging this proprietary drug development platform, our teams of experts will jointly provide seamless one-stop services to our clients, offering enhanced solutions that can help reduce both cost and time, catering to their specific needs.”

 

Samsung Biologics’ CDO business brings quality-driven development services at a greater speed. The company also operates a global R&D center in San Francisco, California, and with the launch of S-Cellerate™, along with its proprietary cell line development platform S-CHOice™, Samsung Biologics continues to provide competitive and innovative service offerings to clients, accelerating the speed of molecules to market.

 

 

SITE MAP

close
Close

Thank you for Subscribing to Our Newsletter

아래 다운로드 버튼을 클릭하시면 바로 다운로드 하실 수 있습니다.

Close

Subscribe to Our Newsletter

파일 다운로드를 위해 뉴스레터 구독용 이메일 주소를 입력해주세요.
* 구독자라면 구독중인 이메일 주소를 입력해주세요.

뉴스레터 구독 서비스 유무 확인
Close

Subscribe to Our Newsletter

뉴스레터 구독 서비스를 등록하시면 당사 뉴스룸에서 제공되는
삼성바이오로직스의 최신 소식과 관심 분야별 유용한 정보를 받아 보실 수 있습니다.

Subscribe to Our Newsletter
    • - 개인정보 수집 목적 : 이메일 발신서비스 제공
    • - 개인정보 수집 항목 : 이메일 주소, 회사명, 이름, 직급, 국가
    • - 이용 및 보관 기간 : 이메일 발신서비스 해지 시까지

    개인정보 수집에 동의하지 않을 시, 뉴스레터 서비스를 이용할 수 없습니다.

    삼성바이오로직스 개인정보 보호정책에 따라 개인정보는 안전하게 관리됩니다.

close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION

Copyright Samsung Biologics. All rights reserved